Form 4: Sarepta Therapeutics CFO Ian Estepan Reports Stock Disposals for Tax Obligations

Chief Financial Officer of Sarepta Therapeutics, Ian Michael Estepan, reports the disposal of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Ian Michael Estepan, the Chief Financial Officer of Sarepta Therapeutics, reported changes in beneficial ownership of the company's stock.
• On March 7, 2024, 526 shares of common stock were disposed of at a price of $120.49 to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.
• On March 8, 2024, 1,035 shares of common stock were disposed of at a price of $123.14 to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.
• Following these transactions, Estepan directly owns 36,164 shares of Sarepta Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's perspective on the company's stock.

Stakeholder Impact

• The disposal of shares by the CFO could be perceived neutrally by shareholders as it is related to tax obligations.

Key Dates